The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis

References

• Rogler G, Vavricka S, Schoepfer A, et al. Mucosal healing and deep remission: What does it mean? Wjg. 2013;19:7552–7560.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–786.
   PubMed Web of Science ®Google Scholar
• Nakarai A, Kato J, Hiraoka S, et al. Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse. Wjg. 2016;22:5079–5087.
   PubMed Web of Science ®Google Scholar
• Korelitz BI. Mucosal healing as an index of colitis activity: back to histological healing for future indices. Inflamm Bowel Dis. 2010;16:1628–1630.
   PubMed Web of Science ®Google Scholar
• Bryant RV, Burger DC, Delo J, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408–414.
   PubMed Web of Science ®Google Scholar
• Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404–409.
   PubMed Web of Science ®Google Scholar
• Mosli MH, Zou G, Garg SK, et al. C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:802–819.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Rosenfeld G, Bressler B, et al. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:742–756.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van AG, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–431.
   PubMed Web of Science ®Google Scholar
• Cioffi M. Laboratory markers in ulcerative colitis: Current insights and future advances. Wjgp. 2015;6:13.
   Google Scholar
• Patel A, Panchal H, Dubinsky MC. Fecal calprotectin levels predict histological healing in ulcerative colitis. Inflamm Bowel Dis. 2017;23:1600.
   PubMed Web of Science ®Google Scholar
• Zittan E, Kelly OB, Kirsch R, et al. Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic crohn’s disease. Inflamm Bowel Dis. 2016;0:1–8.
   Google Scholar
• Theede K, Holck S, Ibsen P, et al. Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2015;13:1929–1936.e1.
   PubMed Web of Science ®Google Scholar
• Guardiola J, Lobatón T, Rodríguez-Alonso L, et al. Fecal Level of Calprotectin Identifies Histologic Inflammation inPatients With Ulcerative Colitis in Clinical and Endoscopic Remission. Clin Gastroenterol Hepatol. 2014;12:1865–1870.
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Nielsen OH, et al. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol. 1991;26:1247–1256.
   PubMed Web of Science ®Google Scholar
• Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohn’s Colitis. 2013;7:322–337.
   Google Scholar
• Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterology. 2006;101:1274–1282.
   PubMed Web of Science ®Google Scholar
• Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29–32.
   PubMed Web of Science ®Google Scholar
• Lasson A, Stotzer P-O, Öhman L, et al. The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26–32.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.
   PubMed Web of Science ®Google Scholar
• Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149:1275–1285.
   PubMed Web of Science ®Google Scholar
• Vinding KK, Elsberg H, Thorkilgaard T, et al. Fecal calprotectin measured by patients at home using smartphones–a new clinical tool in monitoring patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:336–344.
   PubMed Web of Science ®Google Scholar
• Mosli M, Parker CE, Nelson SA, et al. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev. 2017;(5):CD011256.
   PubMed Web of Science ®Google Scholar
• Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of the Nancy histological index for UC. Gut. 2017;66:43–49.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. 2014;12:929–934.
   PubMed Web of Science ®Google Scholar
• Mirsepasi-Lauridsen HC, Holmetoft UB, Halkjaer SI, et al. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease. Scand J Gastroenterol. 2016;51:211–217.
   PubMed Web of Science ®Google Scholar
• Kristensen V, Klepp P, Cvancarova M, et al. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J Crohn’s Colitis. 2015;9:164–169.
   Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (stride): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.
   PubMed Web of Science ®Google Scholar
• Levesque BG, Sandborn WJ, Ruel J, et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015;148:37–51. e1.
   PubMed Web of Science ®Google Scholar